Cogstate Limited revised earnings guidance for the fiscal year ending 30 June 2023. For the year, revenue expected to be approximately 6% to 9% below fiscal year 2022; EBIT is expected to be in the range of 6% to 8% of revenue (4 November 2022 guidance of 20% to 24%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 AUD | +0.43% |
|
+4.42% | -18.34% |
Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
Feb. 22 | Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.34% | 136M | |
+22.15% | 46.56B | |
+45.94% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- CGS Stock
- News Cogstate Limited
- Cogstate Limited Revises Earnings Guidance for the Fiscal Year Ending 30 June 2023